Early Detection Research Network

Lung

PGP9.5 antigens were found to be targets of autoantibodies in newly diagnosed subjects with lung cancer. PGP9.5 is also highly expressed in non-small lung cancer cell line H157, having high invasive potential, and the expression of PGP9.5 in tumor cells enhances their invasive potential in vitro and in vivo.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/38/59
Under Review
Three
The findings of this study show autoantibodies to UCHL1 (PGP9.5) may have diagnostic utility in conjunction with an imaging modality in symptomatic patients.
a9495de036864d978e1d1db997eaeb6d
no
no
Contents
Validation of Protein Markers for Lung Cancer Using CARET Sera and Proteomics Techniques

1.1 To validate the finding from pilot studies with CARET sera of autoantibodies to annexins I and II and PGP9.5 as potential biomarkers for lung cancers before the clinical diagnosis, evaluating sensitivity and specificity by time before diagnosis, treatment arm, gender, histologic type, and smoking status. 1.2 To determine whether a pattern of occurrence of autoantibodies in lung cancer sera may be diagnostic of lung cancer that is not dependent on the occurrence of any particular autoantibody. 1.3 To compare the findings for individual biomarker candidates and combinations of biomarker candidates in participants who were current smokers versus former smokers.